Patients’ Satisfaction with Topical Anti-Glaucoma Medications and Associated Factors at Gondar University Tertiary Eye Care and Training Center, Northwest Ethiopia, 2021

Figures & data

Table 1 Socio-Demographic Characteristics of the Study Participants at Gondar University Tertiary Eye Care and Training Center, Northwest Ethiopia, 2021 (n=395)

Variables		Frequency	Percentage (%)
Age (years)	22–54	100	25.3
	55–63	99	25.1
	64–70	98	24.8
	71–88	98	24.8
Sex	Male	263	66.6
	Female	132	33.4
Education level	Cannot write and read	197	49.9
	Can write and read	85	21.5
	Primary	44	11.1
	Secondary	35	8.9
	College/university	34	8.6
Residence	Rural	241	61.0
	Urban	154	39.0
Religion	Orthodox	324	82.0
	Muslim	60	15.2
	Protestant	11	2.8
Occupation	Farmer	169	42.8
	Government employ	36	9.2
	Private work	38	9.6
	Housewife	93	23.5
	Retire	40	10.1
	Others*	19	4.8
Marital status	Married	341	86.3
	Single	16	4.1
	Divorced	14	3.5
	Widowed	24	6.1

Note: Others* (students, NGO employee, non-employed).

Table 2 Medication, Follow-Up, and Clinical Characteristics of the Study Participants at Gondar University Tertiary Eye Care and Training Center, Northwest Ethiopia, 2021 (n=395)

Variables		Frequency	Percentage (%)
VA	Normal (≥6/12)	98	24.8
	Mild (worse than 6/12)	44	11.2
	Moderate (worse than 6/18)	200	50.6
	Severe (worse than 6/60)	38	9.6
	Blindness (worse than 3/60)	15	3.8
Type of glaucoma	POAG	187	47.4
	PACG	19	4.8
	Secondary Glaucoma	189	47.8
Severity of glaucoma	Early	62	15.7
	Moderate	98	24.8
	Severe	235	59.5
CDR	≤0.65	49	12.4
	0.7–0.85	153	38.7
	≥0.9	193	48.9
Follow up time	Monthly	107	27.1
	Every 2 months	161	40.8
	> 3 months	127	32.2
Missed follow up	No	340	86.1
	Yes	55	13.9
Ocular surface disease	Yes	27	6.8
	No	368	93.2
Type of glaucoma medication	Beta-blocker (Timolol)	394	99.7
	Miotics	9	2.3
	Prostaglandin analog	1	0.3
Other topical medication	Yes	35	8.9
	No	360	91.1
Knowledge about glaucoma	Poor	142	35.9
	Good	253	64.1

Table 3 Factors Associated with Patient Satisfaction with Topical Anti-Glaucoma Medications at Gondar University Tertiary Eye Care and Training Center, Northwest Ethiopia, 2021 (n=395)

Variables	Satisfied n (%)	Unsatisfied n (%)	COR (95% CI)	AOR (95% CI)	p-value
Age (yrs.)
22–54	61 (61)	39 (39)	1.00	1.00
55–63	58 (58.6)	41 (41.4)	0.90 (0.51–1.60)	0.88 (0.46–1.68)	0.693
64–70	69 (70.4)	29 (29.6)	1.52 (0.84–2.75)	1.36 (0.68–2.71)	0.383
71–88	59 (60.2)	39 (39.8)	0.97 (0.55–1.71)	0.67 (0.33–1.37)	0.277
Marital status
Married	215 (63)	126 (37)	1.00	1.00
Single	7 (43.8)	9 (56.2)	0.46 (0.17–1.25)	0.54 (0.17–1.71)	0.292
Divorced	8 (57)	6 (43)	0.78 (0.27–2.30)	0.74 (0.24–2.32)	0.605
Widowed	17 (70.8)	7 (29.2)	1.42 (0.57–3.53)	1.93 (0.70–5.33)	0.204
Medication frequency
Once to BID	238 (63.6)	136 (36.4)	1.00	1.00
TID or more	9 (42.9)	12 (57.1)	0.43 (0.18–1.04)	0.39 (0.13–1.20)	0.101
Side effect
Yes	9 (25.0)	27 (75.0)	1.00	1.00
No	238 (66.3)	121 (33.7)	5.90 (2.70–12.94)	5.39 (2.35–12.37)	<0.001
OSD
Yes	8 (29.6)	19 (70.4)	1.00	1.00
No	239 (65.0)	129 (35.0)	4.40 (1.87–10.33)	4.12 (1.69–10.09)	0.002
Glaucoma type
POAG	124 (66.3)	63 (33.7)	1.00	1.00
PACG	12 (63.2)	7 (36.8)	0.87 (0.33–2.32)	1.08 (0.31–3.73)	0.909
Secondary glaucoma	111 (58.7)	78 (41.3)	0.72 (0.48–1.10)	0.65 (0.40–1.05)	0.078
Glaucoma severity
Early	42 (67.7)	20 (32.3)	1.00	1.00
Moderate	54 (55.1)	44 (44.9)	0.58 (0.30–1.14)	0.68 (0.33–1.40)	0.292
Severe	151 (64.3)	84 (35.7)	0.86 (0.47–1.55)	1.01 (0.51–2.03)	0.973